Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b…
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Data spans seven presentations across both solid tumors and hematologic malignancies, providing…
ElevateBio to Present Nine Abstracts Showcasing Advancements Across its Gene Editing Platform at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
April 27, 2026 17:00 ET | Source: ElevateBio – Posters detail large…
Arbor Biotechnologies to Present Expansion of CNS Editing Platform Capabilities at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
April 27, 2026 17:00 ET | Source: Arbor Biotechnologies Inc - Oral…
Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting
April 23, 2026 12:00 ET | Source: Catheter Precision, Inc. VIVO System…
Society of Actuaries Announces Clar Rosso as Next CEO
CHICAGO, March 25, 2026 /PRNewswire/ -- The Society of Actuaries (SOA), the…
Society Pass Incorporated (Nasdaq: SOPA) Rolls Out M&A Strategy to Capture Potential Significant Valuation Opportunities in Global Landscape of Privately Held Companies
December 15, 2025 10:55 ET | Source: Society Pass Incorporated NEW YORK,…
Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
December 11, 2025 18:22 ET | Source: Mesoblast Limited NEW YORK, Dec.…
TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm…
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear…
